ARTICLE | Clinical News
ABX-MA1: ABGX submitted an IND to begin this quarter a U.S. Phase I trial in 15-30 patients with metastatic melanoma.
January 14, 2002 8:00 AM UTC
Abgenix Inc. (ABGX), Fremont, Calif. Product: ABX-MA1 Business: Cancer Therapeutic category: Angiogenesis, Antibody Target: MUC18 adhesion molecule Description: Humanized monoclonal antibody against...